Continuous release of bone morphogenetic protein-2 through nano-graphene oxide-based delivery influences the activation of the NF-κB signal transduction pathway

Cheng Zhong1
Jun Feng2
Xiangjin Lin1,∗
Qi Bao3,4,∗

1Department of Orthopaedic, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, People’s Republic of China; 2Department of Molecular and Medical Pharmacology, University of California, Los Angeles, CA; 3Department of Plastic and Reconstructive Surgery, Second Affiliated Hospital, School of Medicine, 1Institute of Gastroenterology, Zhejiang University, Hangzhou, People’s Republic of China

*These authors contributed equally to this work

Abstract: Graphene oxide (GO) has been used as a delivery vehicle for small molecule drugs and nucleotides. To further investigate GO as a smart biomaterial for the controlled release of cargo molecules, we hypothesized that GO may be an appropriate delivery vehicle because it releases bone morphogenetic protein 2 (BMP2). GO characterization indicated that the size distribution of the GO flakes ranged from 81.1 nm to 45,749.7 nm, with an approximate thickness of 2 nm. After BMP2 adsorption onto GO, Fourier-transformed infrared spectroscopy (FTIR) and thermal gravimetric analysis were performed. Compared to GO, BMP2-GO did not induce significant changes in the characteristics of the materials. GO continuously released BMP2 for at least 40 days. Bone marrow stem cells (BMSCs) and chondrocytes were treated with BMP2-GO in interleukin-1 media and assessed in terms of cell viability, flow cytometric characterization, and expression of particular mRNA. Compared to GO, BMP2-GO did not induce any significant changes in biocompatibility. We treated osteoarthritic rats with BMP2 and BMP2-GO, which showed significant differences in Osteoarthritis Research Society International (OARSI) scores (P<0.05). Quantitative assessment revealed significant differences compared to using BMP2 and BMP2-GO (P<0.05). These findings indicate that GO may be potentially used to control the release of carrier materials. The combination of BMP2 and GO slowed the progression of NF-κB-activated degenerative changes in osteoarthritis. Therefore, we infer that our BMP2-GO strategy could alleviate the NF-κB pathway by inducing continuous BMP2 release.

Keywords: graphene oxide, BMP2, controlled release, anti-inflammatory

Introduction

Osteoarthritis (OA) is a degenerative joint disease that leads to the destruction of cartilage, followed by reactive hyperplasia of articular cartilage edge, and formation of osteophytes.1 Age, obesity, strain, joint trauma, congenital abnormality, and joint deformity are risk factors for OA.2 Treatment of more advanced stages of OA may involve artificial joint replacement, which is currently recognized as the most effective method that could significantly improve the quality of life of patients.3

Normal bone morphogenetic protein 2 (BMP2) is an important protein component that is involved in the maintenance of the structure and function of cartilage.4 BMP2 expression significantly increases during cartilage damage.5 Thus, it is an important function of BMP2 to maintain the formation of articular cartilage and repair damaged cartilage.4 Inappropriate BMP2 dosages often cause side effects and raise the costs...
of treatment programs after surgery. Serious complications such as immune responses, ectopic bone formation, swelling of surgical site, postoperative tissue injury, and osteolysis are caused by inappropriate administration of BMP2.\textsuperscript{7,8} Therefore, it is necessary to appropriately administer BMP2 to avoid these complications.\textsuperscript{9}

The optimal administration model for BMP2 for the restoration of cartilage is dependent on its delivery vehicle. A number of delivery vehicles that release BMP2 have been evaluated, which include fibrin gels,\textsuperscript{10} poly(lactic-co-glycolic acid) (PLGA),\textsuperscript{11} chitosan,\textsuperscript{12} PLGA nanospheres,\textsuperscript{13} and hydrogels.\textsuperscript{14} The ideal vehicle should reduce BMP2 usage for cartilage protection. Graphene oxide (GO) has been employed as an in vivo delivery vehicle for small molecule drugs and nucleotides because of its steady biocompatibility,\textsuperscript{15} low toxicity,\textsuperscript{16} and excellent loading capacity.\textsuperscript{9,17} One essential characteristic of GO is its hydrophobic π domains in the core, which are ionized along the edges.\textsuperscript{18} GO is a flat monolayer of carbon atoms in a two-dimensional (2D) honeycomb-like structure.\textsuperscript{19} Graphene consists of a six-membered ring π-conjugated monolayer, planar aromatic polymer that facilitates binding of a large number of substances, including metals, drugs, biological molecules, fluorescent probes, and cells.\textsuperscript{21–24} GO has a large specific surface area, strong ion exchange capacity, and contains a large number of carboxyl-, hydroxyl-, and oxygen-containing functional groups, and thus it has good biocompatibility and high drug-loading capacity. The specific surface area of graphene is 2,600 m\textsuperscript{2}/g, which is fivefold higher than that of nanomaterials currently used in drug delivery.\textsuperscript{25} In addition, the oxygen atoms in the six-element ring can form hydrogen bonds with drug molecules, which in turn circumvents molecular aggregation and improves drug efficacy.\textsuperscript{26,27}

In the present study, we investigated whether GO as a vehicle for BMP2 improves the BMP2 effect on cartilage protection. The findings of this study may further expand the applications of GO to the biomedical field, which includes utilization as a novel treatment scheme for osteoarthritis.

Materials and methods

Cell culture

Rat bone marrow stem cells (BMSCs) and chondrocytes were purchased from the Institute of Biochemistry and Cell Biology, CAS (Shanghai, China) and cultured in Dulbecco’s Modified Eagle’s Medium (DMEM; GibcoBRL, Gaithersburg, MD, USA) supplemented with 10% (v/v) fetal bovine serum (FBS, Gibco, Thermofisher Scientific, Waltham, MA, USA). The medium was replaced every 2 days. BMSCs after four passages were used in the experiments. Chondrocytes after three passages were used in the experiments. All the cells were kept at 37°C.

GO characterization

GO flakes were purchased from Chengdu Organic Chemicals Co., Ltd. Chinese Academy of Science (Chengdu, China) and examined by scanning electron microscopy (SEM, JSM-6701F; JEOL, Tokyo, Japan) after platinum coating. The samples were observed under a scanning electron microscope (Hitachi S3000N) at an accelerating voltage of 15 kV. The size distribution of the GO flakes was determined using a zeta electric potential-based spectrophotometer (Zetasizer3000HSA; Malvern Instruments, Malvern, UK). The thickness of the GO flakes was determined by atomic force microscopy (AFM, MultiMode; Veeco, Santa Barbara, CA, USA) coupled with an inverted microscope (IX71 inverted microscope; Olympus, Tokyo, Japan). Thermal gravimetric analysis and differential scanning calorimetry were performed by using a Thermogravimetric Analyzer (TGA)/Differential Scanning Calorimeter (DSC) thermal gravimetric analyzer (Pyris 1 TGA; Perkin-Elmer, Waltham, MA, USA), which involved placing the samples in aluminum pans, which were then heated from 25°C to 1,100°C at a rate of 10°C/min.

BMP2 adsorption onto GO

GO flakes were labeled with 1,1-dioc-tadecyl-3,3,3,3-tetramethylindocarbocyanine perchlorate (DiI; Sigma, St Louis, MO, USA). For BMP2 adsorption, fluorescein isothiocyanate (FITC; Thermo Scientific, Rockford, IL, USA)-conjugated BMP2 (Huan Co., Hangzhou, China) and DiI-labeled GO were mixed with phosphate-buffered saline (PBS) and incubated for 4 h at 4°C. The ratio of GO to BMP2 was 1:1 by weight. To determine the amount of BMP2 that should be loaded onto GO, 1 µg of BMP2 was added to 20 µL of PBS containing GO and incubated for 4 h at 4°C. BMP2 adsorbed onto GO was visualized using a laser scanning confocal microscope (IX81-FV1000 inverted microscope; Olympus). To confirm BMP2 adsorption onto GO, Fourier-transformed infrared spectroscopy (FTIR) was performed using a Nicolet 5700 spectrometer (Thermo Electron Scientific Instruments Corp., Madison, WI, USA) on pellets (10 mm in diameter), which were prepared by mixing 2 mg of samples with 100 mg of KBr in a mortar and pressing, to produce the pellets to be analyzed. Spectra were analyzed after baseline correction by
Release kinetics of BMP2

The release profiles of BMP2 at various concentrations (10 µg/mL, 20 µg/mL, and 20 µg/mL) absorbed onto GO with or without hydrogels were determined by enzyme-linked immunosorbent assays (ELISAs; R&D Systems Inc., Minneapolis, MN, USA). Following incubation for 4 h at 4°C, an ELISA of the supernatant showed that all the BMP2 had adsorbed onto GO. Hydrogel was purchased from SaiYe Co. (Guangzhou, China). Hydrogel was prepared by mixing hydrogel (100 mg/mL) dissolved in PBS solution with 10 mL of that dissolved in a calcium chloride solution (6 mg/mL). The BMP2-loaded GO was resuspended in 0.5 mL of the hydrogel mixture and immersed in a 60 mm culture dish containing 1.5 mL of PBS. The dishes were then incubated at 37°C. At various time points, the supernatant was collected after continuous agitation with a shaker mechanically before removal of sample, and fresh buffer was added to the culture dishes. The concentration of BMP2 in the supernatant was determined using ELISA.

GO biocompatibility assay

The BMSCs and chondrocyte cultures were treated with the GO flakes with 10 µg/mL BMP2 for 1 day, 3 days, 5 days, 7 days, and 10 days. Cell viability was evaluated using the cell counting kit-8 (CCK8) assay as previously described. The absorbance of each sample was measured at a wavelength of 570 nm (n=5 for each group). Giemsa staining assay was performed to determine the activity of BMSCs and chondrocytes cultured with or without GO (BMP2: 20 µg/mL) according to the manufacturer’s instructions. The number of F-actin-positive cells was also counted. Images of 30 different areas in each group were randomly selected, captured, and used in the calculations.

Flow cytometric characterization

BMSCs and chondrocytes were harvested by trypsinization and labeled with the following fluorescent dye: Hoechst33258 and Annexin V-FITC/propidine iodide (PI). Cell cycle staging and cell apoptosis were determined by using a Flow Cytometry Analysis Kit (Lianke, Hang Zhou, China). Labeling was performed for 30 min at 4°C in the presence of a blocking reagent (Lianke), followed by two washing steps using PBS. After washing and fixing, at least 10^4 cells were acquired and analyzed. Flow cytometric analysis was performed using a Becton Dickinson FACSCanto II.

Real-Time quantitative Polymerase Chain Reaction (RT-qPCR)

Total RNA was extracted using an RNA kit and protocol (GenePharma Co., Ltd., Shanghai, China). mRNA contained in 2 µg total RNA was reverse transcribed using a Transcriptor strand cDNA synthesis kit (GenePharma Co., Ltd.). PCR amplification was performed using a SYBRGreen PCR Master Mix (GenePharma Co., Ltd.) and the primers listed subsequently (Integrated DNA(deoxyribonucleic acid) Technologies [IDT], 300 nM). mRNA abundance was quantified using the threshold cycle method.

Collagen I: 5′-TGCTGCTTTTCTCCTCTT-3′, 5′-AAGTGCTGTAAGGAAAT-3′;
Runx2: 5′-TGCTGAGTGATGTTGTTCCT-3′, 5′-CCCCCTGTTGTGTTGTGTTGAA-3′;
Aggrecan: 5′-GCATCCGAACCCCTGAAC-3′, 5′-GGGCTGACCATCATAGTC-3′;
OPN: 5′-CAAATACCCAGATGCTGTGGC-3′, 5′-TCCTGGCTGCACATGGAC-3′;
IRKA4: 5′-ACTTCTTGACAGAGTGCCG-3′, 5′-GGCAGGCGTGGGTGCTGAG-3′;
IKKα: 5′-CCGCTCGAGATGGACCCGTGCTACGA TCC-3′, 5′-GGGTCACCTCAGTGCACCTGGCGT-3′;
IKKβ: 5′-GCCCCAAGGACATCGTCCTT-3′, 5′-CACCGTCTACATTCATGTC-3′; and
NF-κB: 5′-GGAGGCATGTTCGGTAGTG-3′, 5′-CCCTCGTGGCTAGTCTG-3′.

In vivo experiments

The Zhejiang University Ethics Committee approved all experiments performed in rats. The guidelines followed for animals’ welfare was Zhejiang University laboratory animal management regulations (03-2012). Four-week-old male Sprague Dawley rats underwent anterior cruciate ligament transection (ACLT) surgery on both knees as previously described. Immediately after surgery, the animals were returned to their individual cages. Approximately 14 days after ACLT, intra-articular injections of PBS (10 µL/once, n=4), BMP2 alone (20 µg/mL, 10 µL, n=4), and BMP2-GO (20 µg/mL, 10 µL, n=4) were administered to the rats once per week. The rats were all sacrificed 4 weeks after ACLT. The distal femur was dissected, embedded in paraffin, and investigated by staining.
with hematoxylin–eosin (HE), safranin, toluidine blue, and Masson and immunostaining.

OARS1 scoring of cartilage
Semi-quantitative histopathological grading was performed using the Osteoarthritis Research Society International (OARS1) scoring system.29,30 Histological grading was performed in four areas: medial femoral condyle, medial tibial plateau, lateral femoral condyle, and lateral tibial plateau. The grades of four blinded observers for each section were averaged.

Histological and immunohistochemical analysis
Femur–tibia complexes were fixed in 4% formalin for 72 h. Then, the samples were decalcified in 9% formic acid for 2 weeks at room temperature. The samples were dehydrated across an ethanol gradient. Consecutive sections were stained with HE, safranin (Safranin O assay, Sigma S2255), toluidine blue (toluidine blue assay, Amresco 0672, Corporate Headquarters Amresco, LLC, Solon, OH, USA), and Masson (Masson assay, leagene YM-S1453).

Expression of NF-κB, IRAK4, IKKα, and IKKβ at the cartilage interface was analyzed by immunohistochemical staining. The sections were dewaxed in xylene and hydrated across an alcohol gradient. After washing with PBS three times, sections were incubated with a primary antibody for 1 h at 37°C. Then, the samples were incubated with a secondary antibody for 1 h at 37°C. Staining was developed in a 3,3′-diaminobenzidine (DAB) solution (Dako, Santa Barbara, CA, USA). The sections were counterstained with hematoxylin. Immunohistochemical sections were scored based on DAB percentage.

Statistical analysis
All experiments were repeated three times, and the data were expressed as the mean ± standard deviation. One-way analysis of variance (ANOVA) and the Student–Newman–Keuls post hoc test were employed to determine significance levels. P-values less than 0.05 and 0.01 were considered significant and highly significant, respectively. Statistical analysis was performed using SPSS 17.0 (SPSS Inc., Chicago, IL, USA).

Results
GO characterization
2D representation of GO images generated by AFM revealed that the GO flakes were of various sizes and were ~2 nm thick (Figure 1A). The height of the GO flakes (2 nm) also indicated that the GO is a bilayer structure. Furthermore, SEM showed that the GO flakes were irregularly shaped sheets (Figure 1B). The size distribution of the GO flakes based on their electric potential as measured by spectrophotometry ranged from 81.1 nm to 45,749.7 nm, with the most abundant size determined to be 1,598.5 nm (Figure 1C).

BMP2 adsorption onto GO flakes
After incubating DiI (red)-labeled GO and FITC (green)-conjugated BMP2 in PBS for 4 h, BMP2 was determined to have adsorbed onto the GO flakes (Figure 2A). This finding indicated that BMP2 protein effectively adsorbs onto the GO. We investigated the chemical ingredients involved in the GO and BMP2-GO adsorption by FTIR spectroscopy. A peak value of 1,800 cm⁻¹ showed that carboxyl (C=O) was...
BMP2-GO and represents the key role of C=O in adsorption (Figure 2B). We further performed thermal gravimetric analysis of GO using various concentrations of BMP2 with GO (Figure 2C). The curve generated by thermal gravimetric analysis showed no differences between various concentrations of BMP2 but significant differences with GO from 50°C to 200°C.

### BMP2 release

Various concentrations of BMP2 were mixed into the hydrogels with or without GO. Figure 3 shows that the cumulative release profiles of different BMP2 groups were slower in the BMP2 that was mixed into hydrogels and loaded with GO. The cumulative release profiles of different BMP2 groups are also presented in Figure 3. The observed rate of release using 20 µg/mL BMP2 release was apparently faster in reaching a 50% cumulative release compared to 10 µg/mL and 30 µg/mL BMP2. BMP2 was continuously released for at least 40 days at concentrations relevant for chondrocyte protection. This indicated that the application of BMP2 onto GO flakes is a suitable system for prolonged BMP2 release.

---

**Figure 2** BMP2 adsorbed onto GO flakes.

**Notes:** (A) BMP2-FITc and GO-Dil were observed by laser confocal microscopy (bar = 1 mm). (B) FTIR spectroscopy showing the chemical ingredients involved in the interaction between GO and BMP2-GO. A peak value of 1,800 cm⁻¹ showed that carboxyl (C=O) was involved in the process of adsorption. (C) Thermal gravimetric analysis shows no differences between various concentrations of BMP2 but significant differences with GO from 50°C to 200°C.

**Abbreviations:** AFM, atomic force microscopy; BMP2, bone morphogenetic protein 2; FITC, fluorescein isothiocyanate; FTIR, Fourier-transformed infrared spectroscopy; GO, graphene oxide; TGA, thermogravimetric analyzer; GO-DIL, graphene oxide–1,1-dioctadecyl-3,3,3,3-tetramethylindocarbocyanine perchlorate.

**Figure 3** Cumulative release profiles of different BMP2 groups.

**Notes:** 20 µg/mL BMP2 release was apparently faster in reaching a 50% cumulative release compared to 10 µg/mL and 30 µg/mL BMP2. BMP2 was continuously released for at least 40 days. The inset image on the graph is the samples used in the cumulative release test on the constant 37°C.

**Abbreviations:** BMP2, bone morphogenetic protein 2; GO, graphene oxide.
Cell proliferation and viability with BMP2-GO

The proliferation and viability of BMSCs and chondrocytes cultured in BMP2 did not significantly differ from those of cells grown in BMP2-GO or GO (P > 0.05; Figure 4A and B). After differentiation, periodic acid-Schiff (PAS) staining, alkaline phosphatase (ALP) staining, and Giemsa staining of BMSCs indicated that the differentiation effect of BMP2 was not affected by GO (Figure 4C and D). The differentiation and anti-inflammatory effect of BMP2-GO were more distinct than that of BMP2. The mRNA expression of IRAK4, IKKα, IKKβ, and NF-κB significantly decreased (Figure 4E and F). Immunohistochemical analysis of chondrocytes cultured in interleukin 1 (IL1) indicated that the protein expression levels of IRAK4, IKKα, IKKβ, and NF-κB decreased (Figure 4G).

Histological and immunohistochemical analyses in vivo

The animal model of ACLT was done in vitro (Figure 5). The histological features of cartilage after treatment with BMP2 are presented in Figure 5B. The articular cartilage of the control specimens after 4 weeks was thinner after ACLT, whereas thicker articular cartilage was observed in...
continuous release of BMP2

Figure 6A presents the immunohistochemical features of inflammatory cells in cartilage after treatment with BMP2. More inflammatory cytokines were detected in the articular cartilage in the control group 4 weeks after ACLT, whereas a lower amount was observed in the BMP2 group. No inflammatory cytokines were detected in the articular cartilage of the BMP2-GO group 4 weeks after ACLT.

Quantitative assessment revealed significant differences between the control group with BMP2 and the BMP2-GO group (\(P<0.05\), Figures 5C and 6B).

Efficacy of combining BMP2 with GO as an OA treatment

BMP2 with GO was intra-articularly administered to rats to determine whether it can control the progression of inflammation in OA. Approximately 4 weeks after surgery, compared to the OA group (control), OA rats treated with BMP2 and BMP2-GO showed significant differences in OARSI scores (\(P<0.05\)). Furthermore, the BMP2-GO group exhibited an enhanced therapeutic effect and a significantly lower OARSI score compared to the BMP2-only group (\(P<0.05\)), possibly due to the sustained release of BMP2 in the presence of GO (Figure 5D).

Discussion

In the present study, we developed a novel strategy for the treatment of OA, in which BMP2 combined with GO was applied, and the effect of combined BMP2-GO controlled release was compared to that of delivery of BMP2 alone. The present study has three major findings: first, there was a sustained release of BMP2 from GO for 40 days, which should be more therapeutically effective in protecting cartilage; second, GO sustained biocompatibility, as indicated in the results of the in vitro experiment; third, the combination of BMP2 and GO slowed the progression of inflammation and degenerative changes in OA.

Currently, a large variety of biomedical materials have been manufactured that can be used as carriers for tissue regeneration factors. Loading of carriers such as calcium phosphate cements,\(^{31}\) titanium,\(^{32}\) collagen,\(^{33}\) silk,\(^{34}\) and polyactic acid–polyglycolic acid\(^{35}\) through simple adsorption merely resulted in an abrupt release of biological activity, which is apparently physiologically insufficient in resolving the BMP2-GO group. The immunohistochemical features of inflammatory cells in cartilage after treatment with BMP2 are presented in Figure 6A. More inflammatory cytokines were detected in the articular cartilage in the control group 4 weeks after ACLT, whereas a lower amount was observed in the BMP2 group. No inflammatory cytokines were detected in the articular cartilage of the BMP2-GO group 4 weeks after ACLT.

Quantitative assessment revealed significant differences between the control group with BMP2 and the BMP2-GO group (\(P<0.05\), Figures 5C and 6B).

Efficacy of combining BMP2 with GO as an OA treatment

BMP2 with GO was intra-articularly administered to rats to determine whether it can control the progression of inflammation in OA. Approximately 4 weeks after surgery, compared to the OA group (control), OA rats treated with BMP2 and BMP2-GO showed significant differences in OARSI scores (\(P<0.05\)). Furthermore, the BMP2-GO group exhibited an enhanced therapeutic effect and a significantly lower OARSI score compared to the BMP2-only group (\(P<0.05\)), possibly due to the sustained release of BMP2 in the presence of GO (Figure 5D).

Discussion

In the present study, we developed a novel strategy for the treatment of OA, in which BMP2 combined with GO was applied, and the effect of combined BMP2-GO controlled release was compared to that of delivery of BMP2 alone. The present study has three major findings: first, there was a sustained release of BMP2 from GO for 40 days, which should be more therapeutically effective in protecting cartilage; second, GO sustained biocompatibility, as indicated in the results of the in vitro experiment; third, the combination of BMP2 and GO slowed the progression of inflammation and degenerative changes in OA.

Currently, a large variety of biomedical materials have been manufactured that can be used as carriers for tissue regeneration factors. Loading of carriers such as calcium phosphate cements,\(^{31}\) titanium,\(^{32}\) collagen,\(^{33}\) silk,\(^{34}\) and polyactic acid–polyglycolic acid\(^{35}\) through simple adsorption merely resulted in an abrupt release of biological activity, which is apparently physiologically insufficient in resolving
Zhong et al

the inflammation associated with OA. Therefore, a significant feature for the suitability of these biomaterials is the ability to provide controlled release of the biologically active molecules. Based on the literature, we analyzed the main reasons that GO could potentially serve as an excellent carrier of small molecule drugs, which can be summarized as follows: first, GO has a single or bilayer atomic layer structure. Good hydrophilicity allows its complete dispersal in water. Thus, a larger specific surface area and surface activity combined with other dielectric materials facilitate more extensive distribution in a liquid substrate such as water. The specific surface area of GO can reach 2,630 m²/g, whereas that of the common activated carbon is 1,500 m²/g. The larger specific surface area renders graphene as a carrier with high potential.

Second, the oxidation functional group increases the surface activity of GO. This feature can be directly related to the dielectric material that is capable of electrostatic adsorption or bonding that yields a stable composite structure. GO has the ability to self-assemble, similar to a surface active agent. A continuous film tends to form a multilayer structure on a flat solid surface. Most importantly, oxygen-containing groups on the surface of GO molecules may interact with hydroxyl groups of the BMP2 molecules through hydrogen bonding. Third, the atomic layer framework of GO is of good mechanical strength, which may provide mechanical support. At the molecular level, GO molecules are dispersed

Figure 5 Histological analyses in vivo experiment.
Notes: (A) The ACLT model. (B and C) Histological analyses in vivo. Quantitative assessment reveals significant differences between the control group and GO group with BMP2 and the BMP2-GO group (P<0.05; bar =100 µm). (D) OA rats treated with BMP2 and BMP2-GO show significant differences in OARSI scores (P<0.05).
Abbreviations: ACLT, anterior cruciate ligament transection; BMP2, bone morphogenetic protein 2; GO, graphene oxide; HE, hematoxylin–eosin; OA, osteoarthritis; OARSI, Osteoarthritis Research Society International.

International Journal of Nanomedicine downloaded from https://www.dovepress.com/ by 54.70.40.11 on 04-Sep-2018
Figure 6 Immunohistochemistry analyses in vivo experiment.

Notes: (A and B) Immunohistochemistry analyses in vivo. Quantitative assessment reveals significant differences between the control group and GO group with BMP2 and the BMP2-GO group (*P<0.05; bar =100 µm). (C) GO influences the progression of cytokines such as IL-1α, IL-6, IL-10, and TNF-α via the NF-κB pathway.

Abbreviations: BMP2, bone morphogenetic protein 2; GO, graphene oxide; IL, interleukin.
across the matrix and interact with each other. Tensile testing also indicated that tensile strength and Young’s modulus significantly change during these interactions.

Due to their small dimensions and highly developed surface, GO molecules are chemically activated and may behave in an unpredictable manner after their introduction into cells. Thus, it is important to know the detailed mechanisms underlying their interactions with cells both in vitro and in vivo. It has been suggested that carbon particles with diameters <30 µm are deposited in tissues. Schinwald et al suggested that GO molecules may have deposited into tissues and caused acute inflammatory reactions due to their extremely small diameter with large functional surface area. In contrast to previous studies, we observed the effect of GO deposition by HE staining. Due to the lack of conclusive findings on the side effects of GO molecules, we have no detailed evidence that would elucidate the mechanism underlying the interaction between graphene nanomaterials and cells, and the hypothesis that GO nanoparticles cause the dysfunction of mitochondrial activity and increase the concentration of the intracellular reactive oxygen species was still controversial. Graphene can be considered as an immunostimulant for immunotherapy. Most of the experiments, including biological response and safety tests, have been conducted on graphene. Lymphocyte activation using a graphene antibody carrier was observed when therapeutic tumor-infiltrating lymphocytes were infused into a patient, which may have induced the tumor cell lysis and tumor regression. Cells are generally administered to a patient after obtaining the appropriate subpopulation. Understanding the precise mechanism of how this GO nanomaterial influences the immune system may potentially influence the application of graphene to the human body.

The observed prolonged release of BMP2 due to the presence of GO, compared to that of free BMP2, is likely due to the fact that an extended release of BMP2 would provide a continuous benefit for chondrocytes and articular cartilage. The long-term delivery of BMP2 helps cartilage cells avoid apoptosis and prevents the activation of inflammatory factors, which are required for treatment of OA. Blood samples should be collected from living animals to detect whether the drug reached the blood or was just localized in arthrosis. In addition, carbon atoms strongly interact with proteins in the plasma membrane, thereby resulting in changes in the spatial conformation of receptor proteins. The downstream signaling pathways or receptors such as IL-1R may have been activated or inactivated. Cytokines are controlled by regulatory transcription factors, which include NF-κB. Researchers have proven that GO influences the progression of cytokines such as IL-1α, IL-6, IL-10, and TNF-α via the NF-κB pathway (Figure 6C).

The size of a GO molecule is an important factor that affects its function as a drug carrier. When the size of a GO molecule is too small, this may affect drug loading and the drug may be easily phagocytosed. When the size of a GO molecule is too large, this may influence drug transport in the body. The size of GO molecule investigated in this research did not affect drug loading and drug transport.

Conclusion

Current research investigations have focused on elucidating the mechanisms underlying the interaction between 2D GO molecules and cells. Graphene is a novel material whose properties facilitate a wide range of biological applications. However, because graphene occurs in various forms, its toxicology and biological interactions have not been fully elucidated. Information on its 2D carbon structure, particularly its biochemical responses at the tissue interface, thus require additional investigations. Utilization of graphene as a nanomaterial in biomedical applications should thus be established in the near future.

Acknowledgments

The authors obtained financial support from Zhejiang province key science and technology innovation team (Grant No 2013TD13), Zhejiang provincial natural science foundation of China (Grant No LQ16H160006), and National Science Foundation for Distinguished Young Scholars of China (Grant No 81601710).

Disclosure

The authors report no conflicts of interest in this work.

References


